Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific has signed agreements with Daiichi Sankyo and Takeda Pharmaceuticals to use its Oncomine Dx Target Test in clinical trials and drug development programs.

Under the terms of those partnerships, Thermo will validate additional biomarkers and gene variants on Oncomine and retain global commercialization rights for the test. The company will also be responsible for filing supplemental premarket approval applications with the US Food and Drug Administration.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.